Onconova Therapeutics, Inc. (ONTX) Reaches $0.96 Yearly Low; SMA SOLAR TECH (SMTGF) Shorts Down By 0.8%

February 7, 2018 - By Clifton Ray

SMA SOLAR TECH (OTCMKTS:SMTGF) had a decrease of 0.8% in short interest. SMTGF’s SI was 931,000 shares in February as released by FINRA. Its down 0.8% from 938,500 shares previously. With 100 avg volume, 9310 days are for SMA SOLAR TECH (OTCMKTS:SMTGF)’s short sellers to cover SMTGF’s short positions. It closed at $48.71 lastly. It is down 0.00% since February 7, 2017 and is . It has underperformed by 16.70% the S&P500.

The stock of Onconova Therapeutics, Inc. (NASDAQ:ONTX) hit a new 52-week low and has $0.90 target or 6.00% below today’s $0.96 share price. The 6 months bearish chart indicates high risk for the $10.34M company. The 1-year low was reported on Feb, 7 by Barchart.com. If the $0.90 price target is reached, the company will be worth $620,580 less. The stock decreased 11.91% or $0.1298 during the last trading session, reaching $0.9602. About 289,604 shares traded or 16.91% up from the average. Onconova Therapeutics, Inc. (NASDAQ:ONTX) has declined 60.57% since February 7, 2017 and is downtrending. It has underperformed by 77.27% the S&P500.

SMA Solar Technology AG, together with its subsidiaries, develops, produces, and distributes photovoltaic inverters, transformers, choke coils, and monitoring and energy management systems for PV systems worldwide. The company has market cap of $1.79 billion. It operates through Residential, Commercial, Utility, Service, and Other divisions. It has a 77.07 P/E ratio. The firm provides micro and single-phase string inverters under the Sunny Boy brand; three-phase inverters under the Sunny Tripower brand; module optimizers, and single and three phase string inverters under the SMA and Zeversolar brands; energy management solutions, and communication products and accessories; and storage systems, as well as technical solutions for PV systems in PV markets.

Analysts await Onconova Therapeutics, Inc. (NASDAQ:ONTX) to report earnings on March, 26. They expect $-0.72 EPS, down 33.33% or $0.18 from last year’s $-0.54 per share. After $-0.71 actual EPS reported by Onconova Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 1.41% negative EPS growth.

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drug candidates to treat cancer. The company has market cap of $10.34 million. The companyÂ’s clinical-stage product candidates include Rigosertib IV, which is in Phase III clinical trials for patients with higher risk myelodysplastic syndromes ; Rigosertib oral in combination with azacitidine that is in Phase II clinical trials for patients with MDS and acute myelogenous leukemia; and Rigosertib oral, which is in Phase II clinical trials for patients with lower risk MDS. It currently has negative earnings. The Company’s clinical-stage product candidates also comprise Briciclib, which is in Phase I multisite dose-escalation trial for patients with advanced solid tumors; and Recilisib that has completed four Phase I clinical trials for patients with acute radiation syndromes.

Among 2 analysts covering Onconova Therapeutics (NASDAQ:ONTX), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Onconova Therapeutics has $600 highest and $6.0 lowest target. $6’s average target is 524.87% above currents $0.9602 stock price. Onconova Therapeutics had 11 analyst reports since September 3, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Monday, October 9 by H.C. Wainwright. The stock of Onconova Therapeutics, Inc. (NASDAQ:ONTX) has “Hold” rating given on Wednesday, January 17 by Maxim Group. As per Thursday, January 18, the company rating was maintained by H.C. Wainwright. As per Thursday, September 3, the company rating was initiated by H.C. Wainwright. Maxim Group downgraded the shares of ONTX in report on Wednesday, January 31 to “Hold” rating. The company was maintained on Tuesday, December 12 by H.C. Wainwright. As per Tuesday, December 19, the company rating was maintained by H.C. Wainwright. The rating was maintained by Maxim Group on Tuesday, June 6 with “Buy”. The rating was maintained by Maxim Group on Tuesday, August 15 with “Buy”. H.C. Wainwright maintained it with “Buy” rating and $6.0 target in Thursday, November 9 report.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>